K. Shannak et al., NORADRENALINE, DOPAMINE AND SEROTONIN LEVELS AND METABOLISM IN THE HUMAN HYPOTHALAMUS - OBSERVATIONS IN PARKINSONS-DISEASE AND NORMAL SUBJECTS, Brain research, 639(1), 1994, pp. 33-41
In order to determine whether, besides the severe striatal dopamine (D
A) loss, other brain neurotransmitter changes may be a constant bioche
mical feature of idiopathic Parkinson's disease (iPD), we measured the
concentration of the three major brain monoamines noradrenaline (NA),
DA, and serotonin (5-HT) and their metabolites in five rostro-caudal
subdivisions of the hypothalamus of eight control patients and nine pa
tients with morphologically confirmed iPD. In the whole hypothalamus o
f the iPD patients we found a mild to moderate mean reduction of NA (-
52%, P < 0.05), DA (-25%), and 5-HT (-26%). At the subregional level,
the most consistently affected area was the intermediate subdivision o
f the hypothalamus proper where all three monoamines were statisticall
y significantly reduced. Evaluation of individual patient values indic
ated that, in contrast to the constant and severe DA reduction present
in putamen of each of the iPD patients (DA loss ranging from 96% to 9
9%), several of these patients had whole (and subregional) hypothalami
c monoamine values well within the range of controls. We conclude that
, although possibly involved in autonomic and/or endocrine disturbance
s in some patients with iPD, none of the observed monoamine changes in
the hypothalamus is an obligatory feature of iPD. Our study demonstra
tes the need for evaluation of individual patient values rather than m
ean differences in order to permit valid conclusions to be drawn as to
whether an observed neurochemical change can be regarded as specific
to a given brain disorder.